Corton Capital’s Maravai LifeSciences MRVI Stock Holding History

Corton Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-36,468	Closed	-$303K	–	545
2024 Q3	$303K	Buy	36,468 +22,599	+163%	+$195K	0.15%	186
2024 Q2	$99.3K	Buy	+13,869	New	+$120K	0.05%	454
2022 Q2	–	Sell	-10,262	Closed	-$362K	–	456
2022 Q1	$362K	Sell	10,262 -1,264	-11%	-$42.4K	0.16%	178
2021 Q4	$483K	Buy	+11,526	New	+$467K	0.21%	94

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Corton Capital's MRVI Position: Q4 2024 in Review

Corton Capital sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 36,468 shares — an estimated $303K sold.

Corton Capital first reported a position in MRVI in Q4 2021 and held it in 4 quarters. The position peaked at $483K in Q4 2021. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

Corton Capital reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
Corton Capital sold 36,468 Maravai LifeSciences shares in Q4 2024, an estimated $303K.
Corton Capital first reported a position in Maravai LifeSciences in Q4 2021 and held it in 4 quarters.
Corton Capital's Maravai LifeSciences position peaked at $483K in Q4 2021.
185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.